BTIG initiated coverage of Zealand Pharma with a Buy rating and DKK 840 price target. The analyst sees Zealand emerging as a leader in obesity and “commercially de-risked” rare diseases. The firm sees additional room for share upside through several data catalysts later in 2024. The company’s obesity pipeline spans incretins with “best-in-class features” and an amylin analog that could emerge as a preferred next-generation treatment option, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZLDPF:
- Zealand Pharma initiated with a Buy at Berenberg
- Zealand Pharma downgraded to Sell from Buy at Danske Bank
- ZLDPF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Zealand Pharma believes it can compete in weight-loss drug market, FT says
- Zealand Pharma price target raised to DKK 450 from DKK 295 at Morgan Stanley